Nektar Therapeutics (LTS:0UNL)
$ 1.0204 -0.01 (-0.97%) Market Cap: 188.15 Mil Enterprise Value: 51.91 Mil PE Ratio: 0 PB Ratio: 3.85 GF Score: 54/100

Nektar Therapeutics at Jefferies Healthcare Conference (Virtual) Transcript

Jun 03, 2020 / 06:00PM GMT
Release Date Price: $22.64
David Michael Steinberg
Jefferies LLC, Research Division - Specialty Pharma Analyst & Equity Analyst

Hello, everyone, and welcome to the Jefferies Healthcare Conference. I'm Dave Steinberg, analyst at Jefferies. And we are delighted to have with us this afternoon, the management of Nektar. With us today will be Wei Lin, who's Head of Development; and also Jennifer Ruddock, Head of Investor Relations. So there's a lot to talk about. ASCO just got over, EULAR is coming up. And with that, Wei Lin, take it away.

Wei Lin
Nektar Therapeutics - SVP & Head of Development

Okay. Well, thank you so much for the invitation to speak at Jefferies. So we've prepared a slide deck to share with the latest update about our status at Nektar Therapeutics.

And if we go on to the next slide, the Slide 3. So Slide 3 really highlights the breadth and scope of the program at Nektar. We have transitioned ourselves into an immuno-oncology company with a strong focus in our IL pipeline. And in addition, we have ongoing collaborations with both Eli Lilly and as well as

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot